1Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
3Department of Internal medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Introduction:The external beam radiation therapy for patients with left breast cancer at the mastectomy site may cause myocardial perfusion abnormalities. We intended to study the change of these abnormalities at short and long term post radiotherapy follow up. Methods: Twenty patients with left and 20 patients with right breast cancer comprised the exposed and control groups, respectively. The patients had low risk for coronary disease. They underwent myocardial perfusion scans (MPS) 3 years after the external beam radiation therapy at the bed of modified radical mastectomy. These subjects were recruited from two bigger cohorts with previously reported data of scans at 6 months. The scans were acquired after injections of about 20 mCi MIBI at peak pharmacologic stress and at rest. The change of the perfusion abnormalities by both visual assessment and quantifications (Autoquant) at the baseline and 3 years follow up time are compared between exposed and control patients. Results: The exposed patients had more visual perfusion abnormality scores compared to control subjects (1.1±1.3 vs. 0.3±1.0; p=0.03). The indices of perfusion abnormality normalized in control subjects from baseline to follow up scans (p= 0.05 for summed difference score and p=0.04 for summed stress score). The difference of the perfusion abnormalities between the exposed and unexposed subjects remained unchanged along the 3 years of follow up.
Conclusion: The radiation induced myocardial perfusion abnormalities in patients with left breast cancer could cause permanent coronary disease over time.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013 Mar 1;132(5):1133-45.
Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA. 2014 Apr 2;311(13):1327-35.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46.
Lomax ME, Folkes LK, O'Neill P. Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (R Coll Radiol). 2013 Oct;25(10):578-85.
Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012 Mar;177(3):311-27.
Sardaro A, Petruzzelli MF, D'Errico MP, Grimaldi L, Pili G, Portaluri M. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol. 2012 May;103(2):133-42.
Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol. 2012 Oct 20;30(30):3657-64.
Shah C, Badiyan S, Berry S, Khan AJ, Goyal S, Schulte K, Nanavati A, Lynch M, Vicini FA. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiother Oncol. 2014 Jul;112(1):9-16.
Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):845-53.
Eftekhari M, Anbiaei R, Zamani H, Fallahi B, Beiki D, Ameri A, Emami-Ardekani A, Fard-Esfahani A, Gholamrezanezhad A, Seid Ratki KR, Roknabadi AM. Radiation-induced myocardial perfusion abnormalities in breast cancer patients following external beam radiation therapy. Asia Ocean J Nucl Med Biol. 2015;3(1):3-9.
Yusuf SW, Howell RM, Gomez D, Pinnix CC, Iliescu CA, Banchs J. Radiation-related heart and vascular disease. Future Oncol. 2015;11(14):2067-76.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98.
Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer. 2013 Jan 15;108(1):179-82.
Darby SC, Ewertz M, Hall P. Ischemic heart disease after breast cancer radiotherapy. N Engl J Med. 2013 Jun 27;368(26):2527.
Brenner DJ, Shuryak I, Jozsef G, Dewyngaert KJ, Formenti SC. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern Med. 2014 Jan;174(1):158-60.
Rutter CE, Chagpar AB, Evans SB. Breast cancer laterality does not influence survival in a large modern cohort: implications for radiation-related cardiac mortality. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):329-34.
Unal K, Unlu M, Akdemir O, Akmansu M. 18F-FDG PET/CT findings of radiotherapy-related myocardial changes in patients with thoracic malignancies. Nucl Med Commun. 2013 Sep;34(9):855-9.
Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):214-23.
Goethals I, De Winter O, De Bondt P, De Sutter J, Dierckx R, Van De Wiele C. The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol. 2002 Sep;13(9):1331-9.
Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305.
Murtagh G, Lyons T, O'Connell E, Ballot J, Geraghty L, Fennelly D, Gullo G, Ledwidge M, Crown J, Gallagher J, Watson C, McDonald KM, Walshe JM. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat. 2016 Apr;156(3):501-6.
Sandoo A, Kitas GD, Carmichael AR. Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag. 2015 Apr 7;11:223-8.
Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66.
Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993 Oct 27;270(16):1949-55.
Gujral DM, Shah BN, Chahal NS, Senior R, Harrington KJ, Nutting CM. Clinical features of radiation-induced carotid atherosclerosis. Clin Oncol (R Coll Radiol). 2014 Feb;26(2):94-102.
Jin GH, Chen LX, Deng XW, Liu XW, Huang Y, Huang XB. A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different radiotherapy techniques: conventional tangential field, filed-in-filed, tangential-IMRT, multi-beam IMRT and VMAT. Radiat Oncol. 2013 Apr 15;8:89.